Reported 1 day ago
HSBC analyst Rajesh Kumar upgraded Eli Lilly and Company (LLY) from Sell to Hold and increased the price target from $675 to $700, reflecting the company's progress with its oral weight-loss drug, which is expected to gain FDA approval in 2026. This follows a nearly 17% increase in share value since mid-August, after facing a YTD decline of over 5%. The majority of analysts now rate the stock as Buy, with a consensus price target suggesting a potential upside of 23%.
Source: YAHOO